|Day Low/High||160.25 / 162.73|
|52 Wk Low/High||133.64 / 184.21|
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Online News Resource Highlights Importance of Patient and Care Team Dialogue
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.
Jefferies lowered its rating on Amgen stock.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.
XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors
Preclinical Results for Mcl-1 Inhibitor for Multiple Myeloma Accepted as Oral Presentation
Why Jim Cramer likes Taser, Advanced Micro Devices, Amgen and more.
This month's resilience in the market has a lot to do with short squeezes in big tech names.
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval
BLINCYTO is the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S.
Innovative Start-Up Companies Receive One-Year Free Lab Space
First Biosimilar Adalimumab Approved in the European Union
Get your plan in place, but understand that the Republic is not in jeopardy.
Obamacare? Trumpcare? These stocks don't care.
Here's a rundown of four technical setups that are showing solid trading potential.
Cramer shares his views on how the market had a slow, pre-Trump kind of day, and also discusses the next step in Adobe's tech surge.
Results From Two Studies Show Approximately 80 Percent of Prescription Claims in the U.S. Are Initially Rejected
Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial
Here's how to trade six of the most active names on the market this past week.